The Ministry of Health (Minsa)
on Saturday affirmed that the Sinopharm COVID-19 vaccine reached an efficacy of 79.34% in phase III of clinical trials in the United Arab Emirates (UAE), according to the Beijing Institute of Biological Products.
made this clarification after Ernesto Bustamante said in a local TV program that Sinopharm vaccine's Wuhan strain had only 33% efficacy, while the Beijing strain vaccine had 11.5%.
In a statement, Minsa
affirmed that —in addition to the reports of those trials in the UAE— the scientific journal The Lancet published results of phase I and II studies indicating the neutralizing capacity of the vaccine in different age groups.
"We alert the public not to let themselves be surprised by information issued by unofficial sources without any scientific rigor," the Ministry of Health concluded.